A Randomized Controlled Clinical Trial to Evaluate Safety and Effectiveness of CAF + Mucograft® Compared to CAF Alone in Patients With Gingival Recessions

NCT ID: NCT00902876

Last Updated: 2019-02-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-03-31

Study Completion Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this multi-center study is to determine the efficacy and safety of Mucograft® in combination with the coronally advanced flap (CAF) for the treatment of gingival recessions. It is assumed that the CAF combined with Mucograft® will result in improved outcome in terms percentage of root coverage and soft tissue thickness in comparison to CAF alone (control).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary goals of mucogingival surgery have changed with time from maintaining gingival health and prevent further progression of the recession to providing predictable root coverage solving patients' esthetic demands.

Many surgical techniques have been utilized to restore gingival tissue dimensions including the use of autologous soft tissue graft. Longitudinal studies have shown that procedures using pedicle and free grafts are both effective for this purpose. However, since this technique uses epithelialized grafts, it generally results in compromised aesthetics ("patch-like area"). Alternatively free connective tissue grafts (CTG) are used providing similar predictability but resulting in better colour matching. Unfortunately, both techniques are associated with significant patient morbidity due to the wound at the palatal donor site. To avoid patient morbidity, acellular dermal allografts have been used as substitutes for palatal donor tissue, demonstrating the possible and promising use of allograft material. However, since the allograft material is derived from human cadavers; it is associated with ethical concerns and the risk of disease transmission.

In patients with a residual amount of keratinized tissue, the coronally advanced flap (CAF) - first introduce by Norber et al. (1926) - has been demonstrated to be very effective in treatment of multiple and single recessions with advantages in terms of aesthetics and morbidity. Although CAF is a safe and predictable approach for root coverage, the application of this surgical technique in conjunction with autologous or synthetic material was reported to enhance the probability to achieve complete root coverage in Miller Class I and II gingival recessions. A promising option to avoid patient morbidity and the use of autologous transplants or allografts is the use of collagen matrices from porcine origin, such as Mucograft®. Similar devices have been extensively used for guided tissue regeneration procedures. Mucograft® provides an ideal matrix for blood vessel and soft tissue ingrowth, which is likely to improve the results and the predictability of recession coverage procedure using the CAF.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gingival Recession

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mucograft + CAF

Mucograft in combination with coronally advanced flap (CAF)

Group Type EXPERIMENTAL

Mucograft

Intervention Type DEVICE

Collagen Matrix for soft tissue regeneration

CAF

Coronally advanced flap (CAF) alone

Group Type EXPERIMENTAL

Coronally advanced flap (CAF)

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mucograft

Collagen Matrix for soft tissue regeneration

Intervention Type DEVICE

Coronally advanced flap (CAF)

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient (male or female) must be 18 years or older
* The patient must be a candidate for bilateral root coverage procedure
* Recession defects are Miller Class I-II and do not vary more than 2 mm.
* At least one mm keratinized tissue is present.
* Patient shows sufficient plaque control (FMPS \< 20%).
* If patient is of child-bearing potential, the patient confirms not to be pregnant and agrees to take contraception for at least 6 months after surgery.
* The patient is able to comply with the study-related procedures such as exercising good oral hygiene and attending all follow-up procedures
* The patient is able to fully understand the nature of the proposed surgery and is able to provide a signed informed consent.

Exclusion Criteria

* Patient is a heavy smoker (\> 10 cigarettes per day)
* Patient is an insulin dependent diabetic
* General contraindications for dental and/or surgical treatment are present.
* The patient has a history of malignancy, radiotherapy, or chemotherapy for malignancy within the past five years.
* The patient is pregnant or nursing
* The patient is taking medications or having treatments which have an effect on mucosal healing in general (e.g. steroids, large doses of anti-inflammatory drugs).
* The patient has a disease, which affects connective tissue metabolism (e.g. collagenases).
* The patient is allergic to collagen.
* Patients have participated in a clinical trial within the last six months.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Geistlich Pharma AG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mariano Sanz, Prof.

Role: PRINCIPAL_INVESTIGATOR

Department of Periodontology, University Complutense Madrid, Spain

Soren Jepsen, Prof.

Role: PRINCIPAL_INVESTIGATOR

Department of Periodontology, University of Bonn, Germany

Jan Wennström, Prof.

Role: PRINCIPAL_INVESTIGATOR

Department of Periodontology, University of Gothenburg, Sweden

Giovanni Zucchelli, Prof.

Role: PRINCIPAL_INVESTIGATOR

Department of Periodontology, University of Bologna, Italy

Lorenz Uebersax, Dr.

Role: STUDY_DIRECTOR

Geistlich Pharma AG, Wolhusen, Switzerland

Bernd Heinz, Dr

Role: PRINCIPAL_INVESTIGATOR

Private practice Hamburg, Germany

Massimo DeSanctis, Prof.

Role: PRINCIPAL_INVESTIGATOR

Private Practice Firenze

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Prof. Mariano Sanz

Madrid, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

References

Explore related publications, articles, or registry entries linked to this study.

Jepsen K, Stefanini M, Sanz M, Zucchelli G, Jepsen S. Long-Term Stability of Root Coverage by Coronally Advanced Flap Procedures. J Periodontol. 2017 Jul;88(7):626-633. doi: 10.1902/jop.2017.160767. Epub 2017 Mar 17.

Reference Type DERIVED
PMID: 28304210 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

10812-009

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.